查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1405864

膀胱過動症治療市場規模/佔有率/趨勢分析報告：按類型、疾病類型、配銷通路、地區、細分市場預測，2024-2030

Overactive Bladder Treatment Market Size, Share & Trends Analysis Report, By Type (Anticholinergics, Mirabegron, Neuromodulation, Botox), By Disease Type (Idiopathic, Neurogenic), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

膀胱過動症治療市場的成長與趨勢：

根據 Grand View Research, Inc. 的最新報告，到 2030 年，全球膀胱過動症治療市場規模預計將達到 52.5 億美元，預測期內複合年成長率為 4.8%。

提高人們對膀胱過動症（OAB）疾病的認知以及增加研發投資以開發針對這種疾病的新製劑等因素預計將推動全球市場的發展。此外，由於對膀胱過動症藥物和治療方法的高需求而加劇的競爭以及大公司對藥品製造的日益關注也是推動需求成長的重要因素。

人們對 OAB 和尿失禁的認知不斷提高是推動市場成長的主要因素之一。該行業的主要企業已經採取了許多措施來提高人們對膀胱過動症症的認知。例如，2023 年 1 月，市場主要企業Urovant Sciences 與演員兼患者 Holly Robinson Peete 合作進行了宣傳活動。此類舉措有助於提高對治療方案的認知和了解，從而提高治療方法的採用率。

此外，預計在預測期內增加對開發針對 OAB 的創新製劑和治療方法的投資將推動成長。例如，2019 年 11 月，新興企業EBT Medical, Inc. 獲得了 1,000 萬美元的 A 輪融資，用於開發一種非侵入性神經調節技術來治療膀胱過動症。因此，專注於藥物和治療的開發和投資預計將推動地理擴張。

此外，行業參與企業正在採取各種策略，例如聯盟和新產品發布，以保持在這個競爭激烈的市場中的地位。例如，2023年3月，杏林製藥株式會社與住友製藥株式會社合作，開始在台灣和新加坡、香港、印尼等亞洲國家開發、製造和商業化OAB治療藥物Vibegron和越南。這些領先公司之間的合作預計將改善每個國家獲得藥物和治療方法的機會，並進一步推動未來幾年的成長。

膀胱過動症治療市場報告亮點

  • 米拉貝隆製劑將於 2023 年主導市場。這是由於米拉貝隆治療 OAB 的採用率和處方率很高。
  • 依疾病類型分類，特發性膀胱過動症由於其盛行率較高，對 2023 年行業銷售額的貢獻最大。
  • 在配銷通路上，零售藥局佔據市場主導地位。高收益成長歸因於提供 OAB 治療的老牌零售藥局的存在和高患者適用性。
  • 由於輝瑞 (Pfizer, Inc.)、艾伯維 (AbbVie, Inc.) 和 Viatris, Inc. 等主要企業在該地區的存在，北美將在 2023 年膀胱過動症治療市場。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場抑制因素分析
  • 產業分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19感染疾病的影響分析

第 4 章業務分析的類型

  • 膀胱過動症治療市場：類型變異分析
  • 抗膽鹼能藥物
  • 米拉貝隆
  • 肉毒桿菌
  • 神經調節
  • 其他

第5章病種業務分析

  • 膀胱過動症治療市場：疾病類型變異分析
  • 特發性膀胱過動症
  • 神經源性膀胱過動症

第6章配銷通路業務分析

  • 膀胱過動症治療市場：配銷通路波動分析
  • 醫院藥房
  • 零售藥房
  • 其他

第7章 區域業務分析

  • 2023 年及 2030 年膀胱過動症治療市場佔有率（按地區）
  • 北美洲
    • 2018-2030年北美膀胱過動症治療市場
    • 美國
    • 加拿大
  • 歐洲
    • 2018-2030年歐洲膀胱過動症治療市場
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 亞太地區膀胱過動症治療市場，2018-2030
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 泰國
    • 韓國
  • 拉丁美洲
    • 拉丁美洲膀胱過動症治療市場，2018-2030
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • MEA膀胱過動症治療市場，2018-2030
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章競爭形勢

  • 公司分類
  • 策略規劃
  • 2023 年公司市場佔有率分析
  • 公司簡介/名單
    • Pfizer, Inc
    • AbbVie Inc.
    • Astellas Pharma Inc.
    • Medtronic
    • Sumitomo Pharma America, Inc.（Urovant Sciences.）
    • Viatris Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Hisamitsu Pharmaceutical Co., Inc.
    • Macleods Pharmaceuticals Ltd.
    • Endo International plc
Product Code: GVR-4-68040-168-0

Overactive Bladder Treatment Market Growth & Trends:

The global overactive bladder treatment market size is expected to reach USD 5.25 billion by 2030, and is estimated to register a CAGR of 4.8% over the forecast period, according to a new report by Grand View Research, Inc. Factors such as the growing awareness about the overactive bladder (OAB) condition, along with rising R&D investments to develop novel formulations for this disease, are projected to drive the global market. In addition, rising competition owing to high demand for OAB medications and treatments and rising emphasis of major players to manufacture drugs is another vital factor propelling the demand forward.

Rising awareness about OAB and urinary incontinence among the population is one of the major factors bolstering the growth of the market. Various key players operating in the industry undertake numerous initiatives to raise awareness about the overactive bladder condition. For instance, in January 2023, Urovant Sciences, a key player operating in the market, collaborated with actress and patient Holly Robinson Peete under a campaign to bring awareness to OAB. Such initiatives help increase awareness and knowledge about the treatment options thereby increasing treatment adoption.

Moreover, increasing investments to develop innovative formulations and treatments targeting OAB are anticipated to fuel growth over the forecast period. For instance, in November 2019, EBT Medical, Inc., a startup, received funding of USD 10 million in series A for developing noninvasive neuromodulation technology to treat overactive bladder. Thus, developments and investments focusing on medications and treatments are anticipated to fuel the geographic expansion.

Furthermore, industry participants are undertaking various strategies like collaborations and new product launches to maintain their position in this competitive market. For instance, in March 2023, KYORIN Pharmaceutical Co., Ltd. collaborated with Sumitomo Pharma Co., Ltd. to develop, manufacture, and commercialize Vibegron for OAB in Taiwan and other Asian Countries like Singapore, Hong Kong, Indonesia, and Vietnam. Such collaborations among major players are expected to increase the accessibility of drugs and treatments across the countries, which can further propel growth in the coming years.

Overactive Bladder Treatment Market Report Highlights:

  • Mirabegron drug dominated the market in 2023 with a which can be attributed to the high adoption and prescription rate of Mirabegron for treating OAB
  • Among disease-type segments, the idiopathic overactive bladder segment was the largest revenue contributor for the industry in 2023 due to its high prevalence rate
  • In the distribution channel segment, the retail pharmacies dominated the market. The higher revenue growth is attributed to the presence of established retail pharmacies offering OAB drugs and its better patient compatibility
  • North America dominated the market for overactive bladder treatment in 2023 owing to the presence of key players such as Pfizer, Inc., AbbVie, Inc., and Viatris, Inc. across the region

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Segment Definitions
    • 1.1.1. Product Segment
    • 1.1.2. Strength Segment
    • 1.1.3. Distribution Channel Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. Gvr's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information Or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations
  • 1.12. Research Assumptions

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing prevalence of target diseases
      • 3.2.1.2. Rising R&D investments for introducing new treatments
      • 3.2.1.3. Growing awareness about the condition
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Adverse effects associated with medications and treatment.
      • 3.2.2.2. Increasing product recalls
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Type Business Analysis

  • 4.1. Overactive Bladder Treatment Market: Type Movement Analysis
  • 4.2. Anticholinergics
    • 4.2.1. Anticholinergics Market, 2018 - 2030 (USD Million)
  • 4.3. Mirabegron
    • 4.3.1. Mirabegron Market, 2018 - 2030 (USD Million)
  • 4.4. Botox
    • 4.4.1. Botox Market, 2018 - 2030 (USD Million)
  • 4.5. Neuromodulation
    • 4.5.1. Neuromodulation Market, 2018 - 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Other Types Market, 2018 - 2030 (USD Million)

Chapter 5. Disease Type Business Analysis

  • 5.1. Overactive Bladder Treatment Market: Disease Type Movement Analysis
  • 5.2. Idiopathic Overactive Bladder
    • 5.2.1. Idiopathic Overactive Bladder Market, 2018 - 2030 (USD Million)
  • 5.3. Neurogenic Overactive Bladder
    • 5.3.1. Neurogenic Overactive Bladder Market, 2018 - 2030 (USD Million)

Chapter 6. Distribution Channel Business Analysis

  • 6.1. Overactive Bladder Treatment Market: Distribution Channel Movement Analysis
  • 6.2. Hospital Pharmacies
    • 6.2.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.3. Retail Pharmacies
    • 6.3.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.4. Others
    • 6.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. Overactive Bladder Treatment Market Share By Region, 2023 & 2030
  • 7.2. North America
    • 7.2.1. North America Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. Key Country Dynamics
      • 7.2.2.2. Competitive Scenario
      • 7.2.2.3. Regulatory Framework
      • 7.2.2.4. Reimbursement Scenario
      • 7.2.2.5. U.S. Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Key Country Dynamics
      • 7.2.3.2. Competitive Scenario
      • 7.2.3.3. Regulatory Framework
      • 7.2.3.4. Reimbursement Scenario
      • 7.2.3.5. Canada Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. Reimbursement Scenario
      • 7.3.2.5. UK Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Reimbursement Scenario
      • 7.3.3.5. Germany Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Competitive Scenario
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Reimbursement Scenario
      • 7.3.4.5. France Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Key Country Dynamics
      • 7.3.5.2. Competitive Scenario
      • 7.3.5.3. Regulatory Framework
      • 7.3.5.4. Reimbursement Scenario
      • 7.3.5.5. Italy Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Key Country Dynamics
      • 7.3.6.2. Competitive Scenario
      • 7.3.6.3. Regulatory Framework
      • 7.3.6.4. Reimbursement Scenario
      • 7.3.6.5. Spain Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Key Country Dynamics
      • 7.3.7.2. Competitive Scenario
      • 7.3.7.3. Regulatory Framework
      • 7.3.7.4. Reimbursement Scenario
      • 7.3.7.5. Denmark Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Key Country Dynamics
      • 7.3.8.2. Competitive Scenario
      • 7.3.8.3. Regulatory Framework
      • 7.3.8.4. Reimbursement Scenario
      • 7.3.8.5. Sweden Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Key Country Dynamics
      • 7.3.9.2. Competitive Scenario
      • 7.3.9.3. Regulatory Framework
      • 7.3.9.4. Reimbursement Scenario
      • 7.3.9.5. Norway Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Scenario
      • 7.4.2.5. Japan Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Scenario
      • 7.4.3.5. China Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Scenario
      • 7.4.4.5. India Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.4.5. Australia
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Competitive Scenario
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Reimbursement Scenario
      • 7.4.5.5. Australia Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.4.6. Thailand
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Competitive Scenario
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Reimbursement Scenario
      • 7.4.6.5. Thailand Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.4.7. South Korea
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Competitive Scenario
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Reimbursement Scenario
      • 7.4.7.5. South Korea Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Scenario
      • 7.5.2.5. Brazil Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Scenario
      • 7.5.3.5. Mexico Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.5.4. Argentina
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Scenario
      • 7.5.4.5. Argentina Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
  • 7.6. MEA
    • 7.6.1. MEA Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Scenario
      • 7.6.2.5. South Africa Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Scenario
      • 7.6.3.5. Saudi Arabia Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Scenario
      • 7.6.4.5. UAE Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Scenario
      • 7.6.5.5. Kuwait Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Share Analysis, 2023
  • 8.4. Company Profiles/Listing
    • 8.4.1. Pfizer, Inc
      • 8.4.1.1. Overview
      • 8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Strategic Initiatives
    • 8.4.2. AbbVie Inc.
      • 8.4.2.1. Overview
      • 8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Strategic Initiatives
    • 8.4.3. Astellas Pharma Inc.
      • 8.4.3.1. Overview
      • 8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Strategic Initiatives
    • 8.4.4. Medtronic
      • 8.4.4.1. Overview
      • 8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Strategic Initiatives
    • 8.4.5. Sumitomo Pharma America, Inc.( Urovant Sciences.)
      • 8.4.5.1. Overview
      • 8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Strategic Initiatives
    • 8.4.6. Viatris Inc.
      • 8.4.6.1. Overview
      • 8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Strategic Initiatives
    • 8.4.7. Teva Pharmaceutical Industries Ltd.
      • 8.4.7.1. Overview
      • 8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Strategic Initiatives
    • 8.4.8. Hisamitsu Pharmaceutical Co., Inc.
      • 8.4.8.1. Overview
      • 8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Strategic Initiatives
    • 8.4.9. Macleods Pharmaceuticals Ltd.
      • 8.4.9.1. Overview
      • 8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Strategic Initiatives
    • 8.4.10. Endo International plc
      • 8.4.10.1. Overview
      • 8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Strategic Initiatives

List of Tables

  • TABLE 1 List of Secondary Sources
  • TABLE 2 List of Abbreviations
  • TABLE 3 Global Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 4 Global Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 5 Global Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 6 Global Overactive Bladder Treatment Market, By Region, 2018 - 2030 (USD Million)
  • TABLE 7 North America Overactive Bladder Treatment Market, By Country, 2018 - 2030 (USD Million)
  • TABLE 8 North America Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 9 North America Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 10 North America Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 11 U.S. Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 12 U.S. Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 13 U.S. Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 14 Canada Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 15 Canada Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 16 Canada Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 17 Europe Overactive Bladder Treatment Market, By Country, 2018 - 2030 (USD Million)
  • TABLE 18 Europe Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 19 Europe Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 20 Europe Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 21 UK Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 22 UK Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 23 UK Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 24 Germany Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 25 Germany Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 26 Germany Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 27 France Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 28 France Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 29 France Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 30 Spain Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 31 Spain Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 32 Spain Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 33 Italy Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 34 Italy Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 35 Italy Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 36 Denmark Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 37 Denmark Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 38 Denmark Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 39 Norway Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 40 Norway Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 41 Norway Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 42 Sweden Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 43 Sweden Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 44 Sweden Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 45 Asia Pacific Overactive Bladder Treatment Market, By Country, 2018 - 2030 (USD Million)
  • TABLE 46 Asia Pacific Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 47 Asia Pacific Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 48 Asia Pacific Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 49 China Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 50 China Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 51 China Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 52 Japan Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 53 Japan Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 54 Japan Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 55 India Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 56 India Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 57 India Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 58 South Korea Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 59 South Korea Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 60 South Korea Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 61 Australia Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 62 Australia Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 63 Australia Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 64 Thailand Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 65 Thailand Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 66 Thailand Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 67 Latin America Overactive Bladder Treatment Market, By Country, 2018 - 2030 (USD Million)
  • TABLE 68 Latin America Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 69 Latin America Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 70 Latin America Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 71 Brazil Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 72 Brazil Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 73 Brazil Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 74 Mexico Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 75 Mexico Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 76 Mexico Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 77 Argentina Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million),
  • TABLE 78 Argentina Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 79 Argentina Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 80 MEA Overactive Bladder Treatment Market, By Country, 2018 - 2030 (USD Million)
  • TABLE 81 MEA Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 82 MEA Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 83 MEA Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 84 South Africa Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 85 South Africa Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 86 South Africa Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 87 UAE Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 88 UAE Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 89 UAE Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 90 Saudi Arabia Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million),
  • TABLE 91 Saudi Arabia Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 92 Saudi Arabia Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 93 Kuwait Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 94 Kuwait Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 95 Kuwait Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 Overactive bladder treatment market segmentation
  • Fig. 8 Market snapshot, 2023
  • Fig. 9 Market trends & outlook
  • Fig. 10 Market driver relevance analysis (current & future impact)
  • Fig. 11 Market restraint relevance analysis (current & future impact)
  • Fig. 12 PESTEL analysis
  • Fig. 13 Porter's five forces analysis
  • Fig. 14 Global overactive bladder treatment market: Type outlook and key takeaways
  • Fig. 15 Global overactive bladder treatment market: Type movement analysis
  • Fig. 16 Global overactive bladder treatment market, for anticholinergics, 2018 - 2030 (USD Million)
  • Fig. 17 Global overactive bladder treatment market, for mirabegron, 2018 - 2030 (USD Million)
  • Fig. 18 Global overactive bladder treatment market, for Botox, 2018 - 2030 (USD Million)
  • Fig. 19 Global overactive bladder treatment market, for neuromodulation, 2018 - 2030 (USD Million)
  • Fig. 20 Global overactive bladder treatment market, for other types, 2018 - 2030 (USD Million)
  • Fig. 21 Global overactive bladder treatment market: Disease type outlook and key takeaways
  • Fig. 22 Global overactive bladder treatment market: Disease type movement analysis
  • Fig. 23 Global overactive bladder treatment market, for idiopathic overactive bladder, 2018 - 2030 (USD Million)
  • Fig. 24 Global overactive bladder treatment market, for neurogenic overactive bladder, 2018 - 2030 (USD Million)
  • Fig. 25 Global overactive bladder treatment market: Distribution channel outlook and key takeaways
  • Fig. 26 Global overactive bladder treatment market: Distribution channel movement analysis
  • Fig. 27 Global overactive bladder treatment market, for hospital pharmacy, 2018 - 2030 (USD Million)
  • Fig. 28 Global overactive bladder treatment market, for retail pharmacy, 2018 - 2030 (USD Million)
  • Fig. 29 Global overactive bladder treatment market, for others, 2018 - 2030 (USD Million)
  • Fig. 30 Regional marketplace: Key takeaways
  • Fig. 31 Regional outlook, 2022 & 2030
  • Fig. 32 Global overactive bladder treatment market: Region movement analysis
  • Fig. 33 North America overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 34 U.S overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 35 Canada overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 36 Europe overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 37 Germany overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 38 U.K overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 39 France overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 40 Italy overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 41 Spain overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 42 Denmark overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 43 Sweden overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 44 Norway overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 45 Asia Pacific overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 46 Japan overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 47 China overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 48 India overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 49 Australia overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 50 South Korea overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 51 Thailand overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 52 Latin America overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 53 Brazil overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 54 Mexico overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 55 Argentina overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 56 Middle East and Africa overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 57 South Africa overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 58 Saudi Arabia overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 59 UAE overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 60 Kuwait overactive bladder treatment market, 2018 - 2030 (USD Million)